PLX

TentativeAI Memo

Protalix Biotherapeutics

As of 2026-10-18/Confidence medium

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-10-18 • Model: RankAlpha Sentiment Codex

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Report quality notice

peer set is too generic or lacks enough direct operating comparators; small-cap biotech peer set is too weak or includes unrelated comparators for a standard-conviction report

Action

—

Confidence

medium

Horizon

—

Key catalyst

PRX-115 Phase 2 enrollment and timing update • 2027-06-30

Base target: $3 / p=50% prob

Biggest risk

The $25 million Chiesi milestone contributed materially to first-half revenue and should not be treated as recurring product sales. PRX-115 remains in Phase 2, with top-line results not anticipated until the second half of 2027. [#SEC-8K-2026-08-12]

Invalidation

Break below $2 or thesis failure.

What would change my mind?

Second-quarter goods revenue rose to $19.8 million from $15.4 million a year earlier, primarily on higher Elfabrio sales. Protalix reiterated 2026 guidance and reported $40.7 million in cash and short-term deposits at June 30 to support ongoing operations and the RELEASE trial. [#SEC-8K-2026-08-12]

Research note

Recommendation

—

Confidence

medium

As of

2026-10-18

Base target

p=50%

Bull target

p=25%

Bear target

p=25%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

Delivery of 2026 revenue guidance
PRX-115 Phase 2 top-line results
Second-quarter goods revenue rose to $19.8 million from $15.4 million a year earlier, primarily on higher Elfabrio sales.

BearKey bullets

Low analyst coverage and loose equity peers limit valuation confidence.
Milestone revenue makes reported growth less indicative of recurring product demand.
[#SEC-8K-2026-08-12]

WatchKey bullets

PRX-115 Phase 2 enrollment and timing update

Summary

High-level snapshot

Recommendation

Model confidence

medium

Timeframe

Asset

Equity

Trigger

Base case: $3 (p=50%)

Target spread vs base: +33% / -47%

Scenario probabilities

Bull Target: $4 (p=25%)Base Target: $3 (p=50%)Bear Target: $2 (p=25%)

Commentary

The company-confirmed Q2 product-sales increase and reiterated guidance are constructive, consistent with the positive deterministic prior. The packet does not establish a dependable post-release share-price reaction or analyst target and estimate revisions. Recent headline coverage is sparse. Zero-valued sentiment fields denote unavailable measurements, not neutral readings.

As of 2026-10-18 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Bear Case

Drivers

Scannable catalysts and supporting factors

Delivery of 2026 revenue guidance
PRX-115 Phase 2 top-line results

Scenarios

Bull Target (Scenario probability)

$4 / p=25% prob

Base Target (Scenario probability)

$3 / p=50% prob

Bear Target (Scenario probability)

$2 / p=25% prob

Analysis 2026-10-18 · RankAlpha Sentiment Codex

Analysis reference price unavailable. Targets are shown without scenario returns.

Sentiment & Exposure

News Sentiment (30d)

0.00

Social Sentiment (7d)

0.00

Events

Other notable items detected

EVENT2027-06-30
PRX-115 Phase 2 enrollment and timing update
The company reported continuing enrollment in the RELEASE trial for uncontrolled gout. A subsequent update could clarify readout timing; the checked company release did not establish an enrollment-completion date. [#SEC-8K-2026-08-12]
Prob 55.00% • Move 15.00% • Priced-in 25.00%

Short-term Catalysts

Next few weeks

Delivery of 2026 revenue guidance
2026-12-31
Protalix reiterated $78 million–$83 million of 2026 total-revenue guidance, including a $25 million Chiesi milestone. Delivery will test whether Elfabrio and Elelyso product sales support the outlook beyond that milestone. [#8-K-2026-08-12] [#SEC-8K-2026-08-12]
Prob 60% • Move 12% • Priced-in 50%

Long-term Catalysts

Months to a year

PRX-115 Phase 2 top-line results
2027-12-31
Protalix anticipates RELEASE top-line results in the second half of 2027. Efficacy and safety results could materially change the program's value, in either direction. [#SEC-8K-2026-08-12]
Prob 40% • Move 40% • Priced-in 20%

Risks

Low analyst coverage and loose equity peers limit valuation confidence.
Milestone revenue makes reported growth less indicative of recurring product demand. [#SEC-8K-2026-08-12]
PRX-115 enrollment, trial timing, efficacy, safety, and future R&D funding remain material clinical-execution risks. [#SEC-8K-2026-08-12]
Partner purchasing and shipment timing could cause quarterly revenue volatility. [#SEC-8K-2026-08-12]

Peers

Symbol	Summary
TAK	Takeda's Replagal is a Fabry enzyme-replacement comparator. Product competition is relevant; Takeda is not a close equity-valuation peer. Takeda prescribing information
SNY	Sanofi's Fabrazyme is a direct Fabry-treatment comparator, but Sanofi's diversified scale makes its equity multiple unsuitable for PLX. Sanofi company release

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment Codex
Analysis date: 2026-10-18

Loading AI feed…

Symbol

Summary

TAK

Takeda's Replagal is a Fabry enzyme-replacement comparator. Product competition is relevant; Takeda is not a close equity-valuation peer. Takeda prescribing information

SNY

Sanofi's Fabrazyme is a direct Fabry-treatment comparator, but Sanofi's diversified scale makes its equity multiple unsuitable for PLX. Sanofi company release